KETOCONAZOLE

Regulatory status by market Prohibited / restricted / permitted — listing is not approval

Public regulatory text on file for 1 jurisdiction(s), covering 1 countries / territories once regional blocs are expanded. Other markets have no public data here — absence is neither approval nor prohibition. Table updated 2026-09-22.

Compiled from publicly published regulatory texts; conditions are reproduced as published, neither rewritten nor translated. The latest official announcement of the target market prevails — this table is a compiled reference, not a compliance conclusion. Matched on the INCI name; salts, esters and synonyms may be missed. Usability and labelling are for the brand and its responsible person to verify against the full text.

Literature

• Ketoconazole-Loaded Mucoadhesive Nanoemulsions for the Better Management of Topical Fungal Infections: Optimization, In Vitro, Ex Vivo, and In Vivo Assessments.Pharmaceutics · 2026

  In vitro, ketoconazole nanoemulsions enhanced its skin bioavailability and antifungal activity.

  C · Official source
• The in vitro antifungal activity of ketoconazole, zinc pyrithione, and selenium sulfide against Pityrosporum and their efficacy as a shampoo in the treatment of experimental pityrosporosis in guinea pigs.Journal of the American Academy of Dermatology · 1990

  In vitro, ketoconazole observed to inhibit Malassezia growth at 0.001 to 1 micrograms/ml.

  C · Official source

Bibliographic records and finding summaries come from public literature databases; research leads only, not efficacy claims.